A small 2% investment in bitcoin made over a decade ago has grown to represent up to 85% of some Fundstrat clients' portfolios without additional purchases, illustrating bitcoin's extraordinary long-term growth. This shift highlights both the power of compounding returns and the risk of portfolio concentration, as such dominance reduces diversification and increases exposure to bitcoin's volatility. Despite this, many investors remain hesitant to hold bitcoin compared to other assets like gold or stocks. Analyst Tom Lee predicts continued bullish momentum for bitcoin and crypto over the next year, driven by institutional adoption and potential tokenization of trillions in assets, but warns investors to balance growth with risk management.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
